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Objective: Pregnancy-associated plasma protein A (PAPP-A) has prognostic impact in pregnancy and
acute coronary syndrome. Patients with chronic kidney disease have an excessive cardiovascular risk. In
an effort to identify novel risk factors for cardiovascular disease, we investigated the relationship of
PAPP-A with speciﬁc outcomes in diabetic patients undergoing dialysis.
Methods: PAPP-A was measured in 1098 diabetic hemodialysis patients, who participated in the German
Diabetes and Dialysis Study and followed-up for a median of 4 years. By Cox regression analysis, we
assessed the association of baseline levels of PAPP-A with all-cause mortality, combined cardiovascular
events and the speciﬁc outcomes of sudden death, stroke, myocardial infarction and infectious mortality.
Results: Patients had a mean age of 66 ± 8 years (54% male) and median PAPP-A concentration of 17 mIU/
L (IQR 13.4e20.9 mIU/L). Per standard deviation increase in PAPP-A the adjusted risk of sudden cardiac
death increased by 23% (HR 1.23, 95%CI 1.12e1.36). Categorical analyses showed that the patients in the
4th PAPP-A quartile had an adjusted 2.6 fold increased risk of sudden death and 2.8 fold increased risk of
stroke as compared to the patients in the 1st quartile. Similarly, the risk of combined cardiovascular
events was signiﬁcantly elevated by the factor 1.5 in patients of the 4th quartile. Additionally, PAPP-A
levels were associated with infectious deaths and all-cause mortality.
Conclusions: PAPP-A is associated with sudden death, stroke and infectious complications in diabetic
dialysis patients. PAPP-A may be useful for risk assessment and monitoring in populations at high risk of
cardiovascular events.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).a protein A; HR, hazard ratio; IGFBP, insulin like growth factor binding protein; IGF, insulin like growth factor; CKD,
CHF, congestive heart failure; MI, myocardial infarction; BMI, body mass index; TRACE, time resolved ampliﬁed cryptate
diac death; CI, conﬁdence interval; BP, blood pressure; PVD, peripheral vascular disease; LDL, low density lipoproteins;
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Mortality of dialysis patients is excessive; the registry in the
United States (USRDS) reports an annual mortality of >20%. Car-
diovascular disease largely contributes to the excess risk. Diabetic
dialysis patients have a higher comorbidity and even poorer
outcome as compared to non diabetic patients on dialysis [1],
which is reﬂected by a ﬁve year survival of only 35% [2]. Therefore,
identiﬁcation of unknown risk factors is an important task in order
to develop novel interventional strategies.
Pregnancy-associated plasma protein A (PAPP-A) is a zinc-
binding metalloproteinase which cleaves insulin like growth fac-
tor binding proteins, mainly IGFBP-4 [3] thus increasing insulin like
growth factor (IGFs) and so allowing their action. The protein was
ﬁrst described in plasma of pregnant women (1974) [4]. Its con-
centration markedly increases during pregnancy and is 100-fold
elevated in the ﬁrst trimester of pregnancy as compared to
healthy non-pregnant women and men [5,6]. PAPP-A is also used
routinely for screening of chromosomal anomalies in the ﬁrst
trimester of pregnancy [7]. Studies in previous years clearly
demonstrate its signiﬁcance also outside pregnancy, mainly in
coronary artery disease [5] and chronic kidney disease [6,8e10].
Similarly to other proteins, which appear and increase in preg-
nancy, PAPP-A is required for normal growth and prenatal devel-
opment [11], while its increased concentrations later in the life is
connected with pathological states [5,6,12].
In 2001, the presence of PAPP-A was shown for the ﬁrst time in
eroded and ruptured atherosclerotic plaques as well as increased
levels in patients with acute coronary syndrome [5]. It was further
shown that PAPP-A is a predictor of cardiovascular events among
patients presenting with cardiac chest pain [13].
Studies in patients with kidney diseases found a relationship of
PAPP-A to renal function with highest levels in patients on dialysis
[12]. The molecule demonstrated prognostic potential in long-term
hemodialysis patients [8e10] and renal transplant recipients [14].
Its role in speciﬁc cardiac and vascular events is unknown and of
major interest. Patients with CKD represent a high-risk population
for cardiovascular events and the pattern and composition of
adverse events is changing in advanced stages of CKD.
Hence, the aim of our study was to evaluate the relationship of
PAPP-A with adverse clinical events, including sudden death,
stroke, myocardial infarction and infectious deaths in a large cohort
of patients with diabetes undergoing hemodialysis namely partic-
ipants of the German Diabetes and Dialysis Study (4D study).
2. Material and methods
2.1. Study design and participants
The 4D study methodology has previously been reported in
detail [15]. The 4D study was a prospective randomized controlled
trial investigating atorvastatin in 1255 patients with type 2 dia-
betes mellitus, age 18e80 years, and on hemodialysis for less than 2
years. Between March 1998 and October 2002, patients were
recruited in 178 dialysis centers in Germany. The study conformed
with the principles outlined in the Declaration of Helsinki. It was
approved by the medical ethical committee, and all patients gave
their written informed consent before inclusion.
2.2. Data collection
Information on age, gender and smoking status was obtained
through patient interviews. Comorbidities, including the presence
of coronary artery disease (CAD) and congestive heart failure (CHF),
as well as the duration of diabetes mellitus and dialysis treatmentwere reported by the patients' nephrologists. CAD was deﬁned by a
history of MI, coronary artery bypass grafting surgery, percuta-
neous coronary intervention, and the presence of CAD, as docu-
mented by angiography. CHF was deﬁned according to the
classiﬁcation system of the New York Heart Association. Blood
pressure was measured in sitting position. Body mass index (BMI)
was calculated as weight (kg) divided by height (m) squared.
2.3. PAPP-A measurements
PAPP-A was measured in serum samples taken at baseline
before randomization and stored at 80 C. Blood was sampled
before the start of dialysis sessions and administration of heparin or
other medication.
PAPP-A was assessed immunochemically with TRACE (Time
Resolved Ampliﬁed Cryptate Emission) technology based on non-
radiating energy transfer. The commercial kit for PAPP-A determi-
nation (BRAHMS GmbH, Thermo Fisher Scientiﬁc) contains two
different monoclonal antibodies e one is conjugated with euro-
pium cryptate and the other one with the ﬂuorescent agent XL 665.
The antigen (PAPP-A) present in serum samples is sandwiched
between two conjugates. The ﬂuorescent signal measured during
the formation of the antigeneantibody complex by the KRYPTOR
analyzer is proportional to the antigen concentration. The results
are expressed in mIU/L. The intra-assay and inter-assay coefﬁcients
of variation were 9.6% and 8.8%, respectively [16].
2.4. Outcome assessment
The primary endpoint of the 4D study was deﬁned as a com-
posite of cardiac death, non-fatal myocardial infarction (MI) and
stroke, whichever occurred ﬁrst (combined cardiovascular events;
CVE). Sudden cardiac death (SCD) was considered as: death veriﬁed
by terminal rhythm disorders in an electrocardiogram; death
observed by witnesses within 1 h after onset of cardiac symptoms;
death conﬁrmed by autopsy; unexpected death, presumably or
possibly of cardiac origin and in the absence of a potassium level
larger or equal to 7.5 mmol/L before start of the three most recent
hemodialysis sessions. MI was diagnosedwhen at least two of three
criteria were met: typical symptoms; elevated levels of cardiac
enzymes; diagnostic changes in the electrocardiogram. Stroke was
deﬁned as a neurologic deﬁcit lasting longer than 24 h. Computed
tomographic or magnetic resonance imaging was available in all
but 16 cases. The 4D study endpoints were centrally adjudicated by
three members of the endpoint committee blinded to study treat-
ment and according to pre-deﬁned criteria.
For the present analysis, combined cardiovascular events (CVE),
sudden death, MI, stroke, all-cause mortality and deaths due to
infection were all chosen as separate outcome measures. The
categorization of these events was based on the primary judgment
of the endpoint committee during the 4D Study.
2.5. Statistical analysis
Continuous variables were expressed as mean with standard
deviation or median with interquartile ranges, as appropriate.
Categorical variables were expressed as percentages.
The study populationwas divided into quartiles according to the
PAPP-A concentration at baseline: 13.4 mIU/L (quartile 1),
13.5e17.0 mIU/L (quartile 2), 17.1e20.9 mIU/L (quartile 3),
>20.9 mIU/L (quartile 4).
The Cox proportional hazards regression model was used to
estimate hazard ratios (HR) and corresponding 95% conﬁdence
intervals (CI) for the clinical outcomes of combined cardiovascular
events (CVE), sudden death, MI, stroke, all-cause death and death
Table 1
Patient characteristics according to quartiles of PAPP-A at baseline; study population
n ¼ 1098.
Characteristic PAPP-A (mIU/L)
13.4 13.5e17.0 17.1e20.9 >20.9 p-value
n ¼ 276 n ¼ 288 n ¼ 265 n ¼ 269
Age (years) 66 ± 9 65 ± 8 66 ± 8 66 ± 8 0.694
Gender (% men) 42 61 56 61 <0.001
Atorvastatin
treatment (%)
54 48 46 47 0.217
Smoker/ex-smoker
(%)
32 42 44 45 <0.001
Dialysis vintage
(months)
6 ± 6 7 ± 6 9 ± 7 11 ± 7 <0.001
Duration of
diabetes (yrs)
17 ± 9 18 ± 8 18 ± 9 19 ± 9 0.073
Systolic BP (mmHg) 144 ± 23 145 ± 22 147 ± 21 148 ± 22 0.105
Diastolic BP (mmHg) 75 ± 11 76 ± 10 77 ± 11 77 ± 12 0.208
BMI (kg/m2) 29.1 ± 5.1 27.8 ± 4.8 27.1 ± 4.2 25.9 ± 4.4 <0.001
CAD (%) 27 24 35 32 0.031
CHF (%) 36 35 36 38 0.912
Laboratory parameters
Albumin (g/L) 38 ± 3 38 ± 3 38 ± 3 39 ± 3 0.002
Total cholesterol
(mg/dL)
230 ± 46 217 ± 390 219 ± 41 213 ± 40 <0.001
LDL-cholesterol
(mg/dL)
128 ± 32 125 ± 28 127 ± 27 124 ± 30 0.251
HDL cholesterol
(mg/dL)
34 ± 12 35 ± 12 37 ± 12 39 ± 16 <0.001
Triglycerides (mg/dL) 325 ± 210 259 ± 158 237 ± 140 228 ± 139 <0.001
Hemoglobin (g/L) 107 ± 14 109 ± 14 109 ± 13 110 ± 14 0.101
HbA1c (%)
(mmol/mol)
6.9 ± 1.3 6.7 ± 1.2 6.8 ± 1.3 6.5 ± 1.2 0.017
52 ± 9 50 ± 10 51 ± 9 48 ± 10
Calcium (mmol/L) 2.3 ± 0.3 2.3 ± 0.2 2.3 ± 0.2 2.3 ± 0.2 0.583
Phosphate (mmol/L) 1.8 ± 0.5 1.9 ± 0.5 2.0 ± 0.5 2.1 ± 0.5 <0.001
Creatinine (mmol/L) 504 ± 186 592 ± 177 601 ± 115 575 ± 106 <0.001
Values are presented as means (SD) or %.
Abbreviations: BMI, body mass index; BP, blood pressure; HbA1c, glycated hemo-
globin A1c; CAD, coronary artery disease; CHF, congestive heart failure; PVD, pe-
ripheral vascular disease, LDL, low density lipoproteins; HDL, high density
lipoproteins; PAPP-A; pregnancy-associated plasma protein A.
Table 2
Relationship of PAPP-A as continuous variable (per standard deviation) to clinical
outcome.
HR (95% CI) p
Overall mortality Crude model 1.11 (1.04e1.19) 0.002
Adjusted analysis 1.14 (1.06e1.23) <0.001
Combined cardiovascular events Crude model 1.10 (1.02e1.19) 0.012
Adjusted analysis 1.11 (1.02e1.20) 0.012
Sudden death Crude model 1.19 (1.08e1.31) 0.001
Adjusted analysis 1.23 (1.12e1.36) <0.001
Stroke Crude model 1.10 (0.93e1.30) 0.270
Adjusted analysis 1.14 (0.97e1.35) 0.104
Myocardial infarction Crude model 1.02 (0.88e1.18) 0.820
Adjusted analysis 0.99 (0.83e1.16) 0.859
Mortality due to infection Crude model 1.10 (0.95e1.28) 0.201
Adjusted analysis 1.16 (1.00e1.36) 0.055
Signiﬁcant results are given in bold. Boderline signiﬁcance p¼0.055 is given in bold
as well.
HR e hazard ratio; CI e conﬁdence interval; PAPP-A; pregnancy-associated plasma
protein A adjusted analysis - adjusted for age, sex, smoking status, body mass index,
atorvastatin treatment, systolic blood pressure, dialysis vintage, coronary artery
disease, and levels of hemoglobin, HbA1c, albumin, phosphate, creatinine and total
cholesterol.
M. Kalousova et al. / Atherosclerosis 236 (2014) 263e269 265due to infection. The ﬁrst quartile of PAPP-A served as the reference
group. PAPP-A was furthermore analyzed as a continuous variable.
In the continuous analyses, the hazard ratios and 95% CI are given
per standard deviation of PAPP-A concentrations.
All Cox regression analyses were adjusted for potential con-
founders including age, sex, smoking status, body mass index,
atorvastatin treatment, systolic blood pressure, dialysis vintage,
coronary artery disease, and levels of hemoglobin, HbA1c, albumin,
phosphate, creatinine and total cholesterol in the multivariate
analyses.
KaplaneMeier analyses were performed for the outcomes
mentioned above. To compare the curves of the four groups, the
log-rank test was computed.
Furthermore, we investigated PAPP-A in relation to conven-
tional cardiovascular risk factors including age, sex, smoking status,
systolic blood pressure, LDL-cholesterol and HbA1c status. We used
Cox regression and ROC analyses to evaluate the models with a)
conventional cardiovascular risk factors only and b) the addition of
PAPP-A to conventional cardiovascular risk factors, respectively.
All p-values reported are two-sided and a p-value <0.05 was
considered statistically signiﬁcant. Analyses were performed using
SPSS version 19.0.
3. Results
3.1. Patient characteristics and follow-up
Between March 1998 and October 2002, a total of 1255 Cauca-
sian patients were included into the 4D study. The mean follow-up
period was 3.96 years (median 4.0 years) on atorvastatin and 3.91
years (median 4.08 years) on placebo. A total of 1098 patients had a
PAPP-A measurement at baseline. Of those, 534 patients died dur-
ing follow-up, of whom 141 patients died of SCD and 114 due to
infection. A total of 398 patients reached the CVE with MI and
stroke occurring in 169 and 85 patients, respectively.
Mean age of the patients was 66 ± 8 years and median serum
concentration of PAPP-A was 17.0 (IQR 13.4e20.9) mIU/L with
minimum concentration of 6.4 mIU/L and maximum concentration
of 124.7 mIU/L. Patients characteristics according to PAPP-A quar-
tiles at baseline are shown in Table 1.
3.2. Association of PAPP-A levels with adverse clinical outcomes
Baseline PAPP-A levels were signiﬁcantly associated with all-
cause mortality and speciﬁc adverse clinical outcomes. We found
no sex-speciﬁc differences when data were analyzed separately for
men and for women. Detailed analysis of cardiovascular events
revealed a signiﬁcant association of high PAPP-A levels with sudden
cardiac death but not with myocardial infarction. The respective
HRs and corresponding 95% CI are shown in Table 2 (evaluation of
PAPP-A as a continuous variable) and Table 3 (evaluation of PAPP-A
according to quartiles). KaplaneMeier survival curves for overall
mortality, combined cardiovascular events, mortality due to infec-
tion and sudden cardiac death are shown in Fig. 1.
3.2.1. Cardiovascular events
Analysis of speciﬁc cardiovascular events revealed a signiﬁ-
cantly increased risk of sudden death in patients with high PAPP-A
levels (adjusted HR 1.23, 95% CI 1.12e1.36, p ¼ 0.001 for PAPP-A as
continuous variable (per standard deviation), adjusted HR 2.62, 95%
CI 1.54e4.46, p< 0.001 for the 4th vs.1st quartile). Similarly, patients
with high PAPP-A levels had an increased risk of stroke in the
quartile analyses (adjusted HR 2.80, 95% CI 1.30e6.00, p¼ 0.008 for
the 4th vs. 1st quartile). In contrast, no association of PAPP-A with
myocardial infarction was found. Investigating cardiovascularevents combined, patients in the 4th quartile had the unequivocally
worst prognosis (HR 1.46, 95% CI 1.06e2.01, p ¼ 0.022 vs. ﬁrst
quartile, adjusted analysis).3.2.2. Mortality due to infection
Per standard deviation increase in PAPP-A level, patients had a
16% increased risk of infectious death after adjustment for potential
Table 3
Relationship of PAPP-A quartiles to clinical outcome.
PAPP-A
1st quartile 2nd quartile 3rd quartile 4th quartile
13.4 mIU/L 13.5e17.0 mIU/L 17.1e20.9 mIU/L >20.9 mIU/L
HR (95% CI) HR (95% CI) p vs. 1st quartile HR (95% CI) p vs. 1st quartile HR (95% CI) p vs. 1st quartile
Overall mortality
Crude model 1 1.23 (0.95e1.59) 0.118 1.23 (1.00e1.66) 0.053 1.72 (1.35e2.20) <0.001
Adjusted analysis 1 1.35 (1.04e1.76) 0.027 1.34 (10.17-1.77) 0.037 1.98 (1.50e2.62) <0.001
Combined cardiovascular events
Crude model 1 1.02 (0.08e1.36) 0.919 1.23 (0.93e1.63) 0.149 1.33 (1.00e1.75) 0.048
Adjusted analysis 1 1.12 (0.83e1.51) 0.468 1.24 (0.91e1.69) 0.168 1.46 (1.06e2.01) 0.022
Sudden death
Crude model 1 0.99 (0.609e1.65) 0.982 1.07 (0.65e1.65) 0.795 1.83 (1.16e2.88) 0.009
Adjusted analysis 1 1.24 (0.73e2.10) 0.432 1.31 (0.76e2.27) 0.332 2.62 (1.54e4.46) <0.001
Stroke
Crude model 1 1.54 (0.79e3.01) 0.207 2.00 (1.04e3.83) 0.037 1.81 (0.93e3.52) 0.080
Adjusted analysis 1 1.95 (0.97e3.94) 0.061 2.58 (1.26e5.28) 0.010 2.80 (1.30e6.00) 0.008
Myocardial infarction
Crude model 1 1.06 (0.70e1.62) 0.771 1.22 (0.81e1.85) 0.339 0.86 (0.55e1.36) 0.514
Adjusted analysis 1 1.11 (0.72e1.72) 0.631 1.09 (0.69e1.71) 0.716 0.78 (0.47e1.31) 0.347
Mortality due to infection
Crude model 1 1.55 (0.86e2.80) 0.148 1.96 (1.11e3.47) 0.021 2.06 (1.16e3.65) 0.013
Adjusted analysis 1 1.75 (0.95e3.23) 0.072 2.28 (1.23e4.23) 0.009 2.92 (1.54e5.54) 0.001
Signiﬁcant results are given in bold.
HR e hazard ratio; CI e conﬁdence interval; PAPP-A; pregnancy-associated plasma protein A adjusted analysis - adjusted for age, sex, smoking status, body mass index,
atorvastatin treatment, systolic blood pressure, dialysis vintage, coronary artery disease, and levels of hemoglobin, HbA1c, albumin, phosphate, creatinine and total
cholesterol.
Fig. 1. KaplaneMeier curves showing A All-cause mortality (log-rank test 1st vs. 4th quartile: <0.001), B Combined cardiovascular events (log-rank test 1st vs. 4th quartile: 0.045), C
Death due to infection (log-rank test 1st vs. 4th quartile: 0.012), D Sudden cardiac death (log-rank test 1st vs. 4th quartile: 0.009) in subgroups of patients according to baseline PAPP-
A serum levels (quartile 1: 13.4 mIU/L; quartile 2: 13.5e17.0 mIU/L; quartile 3: 17.1e20.9 mIU/L; quartile 4: >20.9 mIU/L). PAPP-A; pregnancy-associated plasma protein A.
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Fig. 2. ROC curves for the model with conventional cardiovascular risk factors
(including LDL-cholesterol, HbA1c, systolic blood pressure, age, smoking and sex) as
compared to the model with the conventional cardiovascular risk factors and PAPP-A.
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was tested according to quartiles, patients in the 3rd and 4th quar-
tiles had evidently worse prognosis compared with the 1st quartile
(3rd quartile: HR 2.28, 95% CI 1.23e4.23, p ¼ 0.009 vs. 1st quartile;
4th quartile: 2.92, 95% CI 1.54e5.54, p < 0.001 vs. 1st quartile,
adjusted analysis).
3.2.3. All-cause mortality
Univariate Cox regression analyses revealed an 11% increase in
all-cause death (HR 1.11, 95% CI 1.04e1.19, p < 0.001) per standard
deviation increase in PAPP-A. This association persisted after
adjustment for confounders (HR 1.14, 95% CI 1.06e1.23, p < 0.001,
adjusted analysis). When PAPP-A was tested according to quartiles,
patients in the 4th quartile had an almost 2-fold increased risk as
compared to the patients of the ﬁrst quartile (adjusted HR 1.98, 95%
CI 1.50e2.62, p < 0.001). Patients of the second and third PAPP-A
quartile also had a signiﬁcantly worse prognosis as compared to
patients of the 1st quartile.
3.3. Comparison of PAPP-A with conventional cardiovascular risk
factors in the association with mortality
By Cox regression and ROC analyses, we investigated PAPP-A in
relation to conventional cardiovascular risk factors including age,
sex, smoking status, systolic blood pressure, LDL-cholesterol and
HbA1c status (Table 4 and Fig. 2). Themodel including conventional
cardiovascular risk factors only yielded an area under the ROC curve
of 0.63 (95% CI 0.60e0.67). With addition of PAPP-A to the model,
the area under the ROC curve increased to 0.66 (95% CI 0.63e0.69).
4. Discussion
Our study demonstrates a relationship of PAPP-A to the speciﬁc
cardiovascular outcomes sudden cardiac death and stroke in pa-
tients with diabetes mellitus on maintenance hemodialysis. Our
results, in a large patient population, furthermore prove PAPP-A to
be useful as a prognostic marker for all-cause and infectious mor-
tality in diabetic hemodialysis patients.
PAPP-A is produced bymany cell types, both in reproductive and
non-reproductive tissues. These cell types include ﬁbroblasts,
vascular smooth muscle cells, endothelial cells, osteoblasts and
granulosa cells [17]. It is not synthesized in, but rather is bound and
internalized by macrophages [18]. However, macrophages can
contribute to PAPP-A overexpression due to production of proin-
ﬂammatory cytokines IL-1 beta and TNF alpha [19]. By degrading of
some, but not all IGFBPs, especially IGFBP-4 [3], PAPP-A allows IGF-
1 to bind to its receptors and so to exert its action. Some studies
ascribe IGF-1 pro-atherosclerotic properties such as chemotaxis,
LDL uptake and the release of proinﬂammatory cytokines by mac-
rophages [20,21] while others describe IGF-1 as an anti-
atherosclerotic molecule with anti-apoptotic, anti-inﬂammatoryTable 4
Association of PAPP-A and conventional cardiovascular risk factors with mortality;
per standard deviation.
Parameter HR (95% CI) p-value
PAPP-A 1.15 (1.07e1.23) <0.001
LDL-C 1.00 (0.91e1.09) 0.914
HbA1c 1.14 (1.05e1.24) 0.002
Systolic BP 1.04 (0.95e1.13) 0.403
Smokinga 1.26 (1.03e1.54) 0.025
Age 1.49 (1.35e1.64) <0.001
Sex (female)b 0.93 (0.76e1.15) 0.514
a The risk is presented as compared to non-smokers.
b The risk is presented as compared to male sex.and antioxidant effects [22]. It was proposed that PAPP-A might be
a cause of pathology but also a tool to increase IGF-1 and might
increase as a reaction to IGF-1 decrease [23]. IGF-1 unlike PAPP-A
was not an independent mortality predictor in hemodialysis pa-
tients [10]. PAPP-A plays a critical role in the development of
atherosclerotic lesions as shown in animal models. PAPP-A knock
out (KO) mice showed little or no lesion development; PAPP-A KO/
ApoE KO (ApoE KO representing a mouse model of atherosclerosis)
fed with high fat diet had the same number of lesions compared to
ApoE KO mice, but 60e80% reduction in aortic lesion area despite
similar cholesterol and triglyceride levels [24]. Overexpression of
PAPP-A (PAPP-A Tg, transgene) in arterial smooth muscle acceler-
ated lesion progression in a mouse model of atherosclerosis [25].
On the other hand, PAPP-A is required for wound healing [26],
fracture repair [27] and PAPP-A deﬁcient mice are resistant to
neointimal formation after injury [28]. Further data suggest dif-
ferential effects of chronic (transgenic) and transient (endogenous)
PAPP-A expression on neointimal formation following vascular
injury: PAPP-A Tg mice had 70e75% less neointima than wildtype
mice 5e10 days after model injury [29].
Our study describes the relationship of PAPP-A to mortality of
diabetic patients with end-stage renal disease treated with hemo-
dialysis. It demonstrates for the ﬁrst time the association with
speciﬁc cardiovascular events in a representative patient popula-
tion. This association was addressed neither in a study with 261
long-term hemodialysis patients followed-up for 5 years [10] nor in
the study by Etter et al. [9] with smaller number of deaths during
the follow-up period (170 patients, 23 months).
Subanalysis of speciﬁc cardiovascular events pointed out the
signiﬁcance of PAPP-A for sudden death and stroke but not for
myocardial infarction. PAPP-A might reﬂect the presence of un-
stable plaques and might also represent a marker that indicates an
unfavorable state with high levels being at risk for sudden death.
Diabetic patients on dialysis frequently die suddenly; sudden death
accounts for one quarter e and therewith the highest proportion-
of deaths in these patients. Risk factors found so far includedmicro-
and macrovascular disease, sympathetic overactivity, structural
heart disease and electrolyte and volume shifts due to the hemo-
dialysis procedure. However, these risk factors did not fully explain
the excess risk of sudden death. PAPP-A may therefore be useful in
M. Kalousova et al. / Atherosclerosis 236 (2014) 263e269268risk assessment and monitoring, with patients of the highest
quartile showing a more than 2.5 fold increased rate of sudden
death as compared to those in the ﬁrst quartile. Concerning stroke,
we have previously demonstrated increased PAPP-A levels in pa-
tients with intracranial hemorrhage and in patients whose
ischemic stroke was associated with coronary artery disease
compared to healthy controls and to patients with isolated
ischemic stroke [17]. In another study, PAPP-A expression was
higher in both, vulnerable and ruptured carotid plaques and asso-
ciated with activated macrophages as compared to stable plaques.
Serum PAPP-A levels were also increased in these patients [30]. A
recent study of 2568 patients presenting with chest pain demon-
strated an independent association of higher levels of serum PAPP-
A with short term risk of cardiovascular events (90 days) e
myocardial (re)infarction, ischemic stroke and cardiovascular-
related death [13]. Mean serum levels of PAPP-A in that study
were 24.6 ± 50.2 mIU/L (range 4.1e2154.4 mIU/L), the median was
14.0 mIU/L (interquartile range 9.3e25.2 mIU/L). The concentration
of 34.6 mIU/L was set as the best prognostic cut-off (HR 5.28, 95% CI
3.81e7.31) [13]. Lack of any association of PAPP-A levels with
myocardial infarction in our study was surprising, but could be
explained in part by the discrepant nature of previous studies.
Additionally, cardiovascular disease in end-stage renal disease pa-
tients differs from cardiovascular disease in the general population
mainly due to a higher prevalence of calciﬁcations and difference in
atherosclerotic plaque stability.
PAPP-A is also linked to mortality due to infection as demon-
strated in this study as well as in our previous investigation [10].
PAPP-A expression in human atherosclerotic plaques is enhanced
by proinﬂammatory cytokines [17,19]; association with some
proinﬂammatory mediators in serum in patients with kidney dis-
eases such as TNF alpha and IL-6 was also described [14], while the
relationship to C-reactive protein has not always been found
[14,10]. As such, it might reﬂect protein-energy wasting resulting in
an instability of atherosclerotic plaques and worse prognosis of the
patients. This can be supported by our ﬁnding that patients of the
highest PAPP-A quartile had the lowest BMI, total cholesterol and
triglyceride concentrations as indicators of protein-energy wasting.
Peripheral vascular disease was the major cause of hospitalization
(34%) during follow-up and the diabetic foot syndrome may have
induced inﬂammation resulting in an increase in PAPP-A.
Tertti and coworkers observed an increase of PAPP-A after
heparin administration [31]. That is why controversy about previ-
ous studies exists as heparin might have been administered in
many patients before blood collection for PAPP-A analysis. PAPP-A
was described as a marker for vulnerable plaques in patients with
non-ST-segment elevation acute coronary syndrome and its in-
crease was ascribed to the release from the vulnerable plaque [32].
In a subsequent publication Iversen et al. explained the increase by
heparin administration and not due to excretion from vulnerable
plaques [33]. However, Hajek et al. conﬁrmed PAPP-A increases
even in heparin naive patients with acute coronary syndromes [34].
For measurement of basal values, in this study as well as in our
previous investigations, blood was taken before heparin adminis-
tration to avoid its inﬂuence. However, it still remains questionable
whether repeated heparin administration during each hemodialy-
sis as well as repeated intravenous iron administration [35] could
also contribute to slight chronic PAPP-A increases apart from loss of
kidney function and a proinﬂammatory state.
Methodology used for PAPP-A determination is another point
that has to be addressed. PAPP-A exists in a complexed form rep-
resenting the predominant form in pregnancy [36]. It also exists in
a free form, which is most likely the only relevant form in acute
coronary syndromes [37]. In hemodialysis patients, both total and
free PAPP-A are increased [31]. The assay used in this studydetected both forms. As in our previous studies, using the same
assay, we disclosed increases during hemodialysis after heparin
administration [38,39]. This increase should be caused by an in-
crease of free PAPP-A [31]. PAPP-A is cleared rapidly, the majority
with a half-life of 13 min [40]. Usefulness of this assay was
demonstrated even in predicting cardiovascular events in 2568
patients with cardiac chest pain [13].
Potential limitations of our study need to be acknowledged.
PAPP-A concentrations measured in this study were lower than in
previous studies [9,10] although the same method was used for
PAPP-A determination. Patients in this study had round 30%
reduced median and quartile PAPP-A levels but also lower serum
creatinine level than in a previous one [10] and we cannot exclude
potential effect of different long-term dialysis treatment and
medication on PAPP-A levels. Samples were stored at 80 C for
more than ten years until analysis and the effect of such a long time
of storage on PAPP-A levels has not yet been tested. However,
despite lower values in thewhole study our ﬁndings are in linewith
previous studies showing a worse prognosis of hemodialysis pa-
tients with higher PAPP-A levels, especially in the highest quartile.
In conclusion, our study shows a signiﬁcant role of PAPP-A for
cardiovascular events, speciﬁcally for sudden death and stroke, in
patients with diabetes on dialysis. Together with the association
with mortality due to infection PAPP-A might reﬂect a general
unfavorable status and ﬁt into the concept of progressive athero-
sclerotic disease. PAPP-A may be useful for risk assessment and
monitoring in diabetic hemodialysis patients.Funding sources
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